Panel Discussion: Moving to a Patient-Led Ecosystem: How Foundations, Patients & Non-Profit Stakeholders Are Reshaping IPF & PPF Drug Development
10:30 am - Tuesday 29th September 2026
This session will explore how patient organizations, philanthropic foundations, and non-traditional stakeholders are influencing the future of IPF, PPF, and ILD drug development, from translational research funding and biomarker development to trial design, regulatory engagement, and patient access.
- Explore how advocacy groups and research-focused foundations are shaping priorities across the IPF and PPF development landscape
- Discuss the growing role of philanthropic and non-profit organizations in funding translational research, biomarker development, and early-stage therapeutic innovation
- Examine opportunities to accelerate therapy development through collaboration across academia, foundations, biotech, pharma, and patient communities
- Identify practical approaches for building long-term partnerships that extend beyond recruitment into sustained scientific and strategic collaboration
- Assess how patient-informed initiatives are influencing endpoint development, earlier diagnosis strategies, and future treatment paradigms
